Literature DB >> 19390314

Late effects of Hodgkin's disease and its treatment.

Andrea K Ng1, Peter M Mauch.   

Abstract

Long-term survivors of Hodgkin's lymphoma are at increased risk for a number of late complications, including development of second malignancies and cardiovascular disease. Treatment-related factors and other modifying risk factors contributing to the risk of late effects have been identified. Survivors deemed at increased risk based on their treatment history and other exposures may benefit from early detection for late complications and risk reduction strategies. However, the optimal screening tests and prevention program, and their timing and frequency are not clear. It should be noted that treatment for Hodgkin's lymphoma has undergone considerable changes over the last several decades. Most of the current data on late effects after Hodgkin's lymphoma are based on patients treated with outdated chemotherapy and radiation therapy. As Hodgkin's lymphoma therapy evolve over time, continued documentation of late effects associated with newer treatment will be important for the follow-up of patients treated in the modern era.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390314     DOI: 10.1097/PPO.0b013e31819e30d7

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  10 in total

Review 1.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

2.  Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Authors:  Knut B Smeland; Cecilie E Kiserud; Grete F Lauritzsen; Unn-Merete Fagerli; Ragnhild S Falk; Øystein Fluge; Alexander Fosså; Arne Kolstad; Jon H Loge; Martin Maisenhölder; Stein Kvaløy; Harald Holte
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 3.  Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Authors:  Ralph M Meyer; Richard T Hoppe
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

4.  Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

Authors:  Leo I Gordon; Fangxin Hong; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Patrick J Stiff; Bruce D Cheson; Mary Gospodarowicz; Ranjana Advani; Brad S Kahl; Jonathan W Friedberg; Kristie A Blum; Thomas M Habermann; Joseph M Tuscano; Richard T Hoppe; Sandra J Horning
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

5.  Partitioning of excess mortality in population-based cancer patient survival studies using flexible parametric survival models.

Authors:  Sandra Eloranta; Paul C Lambert; Therese M L Andersson; Kamila Czene; Per Hall; Magnus Björkholm; Paul W Dickman
Journal:  BMC Med Res Methodol       Date:  2012-06-24       Impact factor: 4.615

6.  Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.

Authors:  Sheeraz Ali; Abdul Basit; Ather S Kazmi; Armughan Sidhu; Farhana Badar; Abdul Hameed
Journal:  Pak J Med Sci       Date:  2016 Nov-Dec       Impact factor: 1.088

7.  International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Authors:  Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace
Journal:  Qual Life Res       Date:  2017-11-10       Impact factor: 4.147

8.  Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens.

Authors:  Ahmad Ahmadzadeh; Mir Saeed Yekaninejad; Mohamad H Jalili; Mohammad Bahadoram; Mehdi Efazat; Mohammad Seghatoleslami; Fatemeh Yazdi; Mozhdeh Mahdipour; Armita Valizadeh; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

9.  Radiation - friend or foe? Presidential address to Ulster Medical Society 4th October 2012.

Authors:  Roy Spence
Journal:  Ulster Med J       Date:  2014-09

10.  Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab.

Authors:  Lukas Šalaševičius; Goda Elizabeta Vaitkevičienė; Ramunė Pasaulienė; Rosita Kiudelienė; Ernesta Ivanauskaitė-Didžiokienė; Donatas Vajauskas; Nemira Jurkienė; Jelena Rascon
Journal:  Medicina (Kaunas)       Date:  2020-03-31       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.